Loading...
•
Mar 31, 2024
Maravai Q1 2024 Earnings Report
Reported financial results, focusing on product portfolio expansion, market leadership, and scientific innovation.
Key Takeaways
Maravai LifeSciences reported a decrease in revenue to $64.2 million, a net loss of $(22.7) million, and an adjusted EBITDA of $7.8 million for Q1 2024. The company reaffirmed its full-year revenue guidance of $265.0 million to $285.0 million.
Quarterly revenue reached $64.2 million.
Net loss amounted to $(22.7) million.
Adjusted EBITDA was reported at $7.8 million.
Full-year 2024 revenue guidance reaffirmed at $265.0 million to $285.0 million.
Revenue by Segment
Forward Guidance
Maravai expects full year 2024 revenue to be in the range of $265.0 million to $285.0 million and Adjusted EBITDA margins are expected to be in the range of 23% to 25%.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...